---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017857"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:48:47.975956+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia

## Summary
- Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.
- Cash, equivalents and investments $937.8M vs ~$1B at Dec 31 2022; expected to fund operations into 2025.
- Initial RLY-2608 data at AACR: no Grade 3 hyperglycemia/rash/diarrhea at target exposures; one confirmed partial response in breast cancer patient after cut-off.
- RLY-5836 first-in-human trial initiated in April 2023 for PIK3CA-mutant solid tumors; RLY-2139 candidate selected, clinical start early 2024.
- Full RLY-4008 dose escalation data accepted at ASCO 2023; expansion cohorts for RLY-2608 planned H2 2023.

## SEC filing metadata
- accession: 0000950170-23-017857
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/0000950170-23-017857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/rlay-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017857
- JSON: https://secwatch.observer/filing/0000950170-23-017857.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017857.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported the first quarter of 2023 results: net income $94.2 million, EPS $0.78.
  - Period: the first quarter of 2023
  - Net income: $94.2 million
  - EPS: $0.78
  - Result: reported results
  source text: Net loss was $94.2 million for the first quarter of 2023, or a net loss per share of $0.78, as compared to a net loss of $62.0 million for the first quarter of 2022, or a net loss per share of $0.57.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017023017857/0000950170-23-017857-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.